BMS 777607

• Description :

  BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity versus all other receptor and non receptor kinases[1].

• Product Name Alternative :

  BMS 817378

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  C-Met/HGFR; TAM Receptor

• Type :

  Reference compound

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/BMS-777607.html

• Purity :

  99.36

• Solubility :

  DMSO : 83.33 mg/mL (ultrasonic)

• Smiles :

  O=C(NC1=CC=C(C(F)=C1)OC2=C(C(N)=NC=C2)Cl)C3=C(C=CN(C3=O)C4=CC=C(C=C4)F)OCC

• Molecular Formula :

  C25H19ClF2N4O4

• Molecular Weight :

  512.89

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Schroeder GM, et al. Discovery of N- (4- (2-amino-3-chloropyridin-4-yloxy) -3-fluorophenyl) -4-ethoxy-1- (4-fluorophenyl) -2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J Med Chem. 2009 Mar 12;52 (5) :1251-4.|[2]Dai Y, et al. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. Mol Cancer Ther, 2010, 9 (6), 1554-1561.|[3]Dai Y, et al. Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation. Clin Exp Metastasis, 2012, 29, 253-261.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  Axl; Tyro3

• CAS Number :

  [1025720-94-8]